Bluebird bio Profit Margin

The latest profit margin for BLUE is -192.39% as of March 2025. That compares with -663.09% in the prior-year period — up 71.0% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside Bluebird bio's historical trend and sector peers before judging valuation or financial health.

Over the past year, BLUE's profit margin moved from -663.09% to -192.39% — a 71.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bluebird bio's valuation or profitability profile.

Against Healthcare companies, BLUE currently prints -192.39% for profit margin, while the sector average sits near 21.34%. That is roughly 1001.8% below the sector mean. Large gaps often invite a closer look at Bluebird bio's growth, margins, and balance sheet.

Profit Margin shows how effectively Bluebird bio converts resources into returns. At -192.39%, BLUE may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -663.09% in the prior-year period — up 71.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BLUE's profit margin (-192.39%), review year-over-year change from -663.09%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.